Actively Recruiting
Long-term Open-label Study of Iptacopan to Assess Safety and Effectiveness in Adults With Atypical Hemolytic Uremic Syndrome aHUS Who Completed a Prior Phase 3 Iptacopan Trial
Led by Novartis Pharmaceuticals · Updated on 2026-06-04
65
Participants Needed
9
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the long-term safety, tolerability, and effectiveness of iptacopan in adults with atypical Hemolytic Uremic Syndrome aHUS. It is a multicenter, single arm, open-label extension study involving participants who have completed a prior iptacopan Phase 3 trial for aHUS. This study aims to monitor ongoing outcomes and potential benefits of continued treatment with iptacopan over an extended period. Participants will receive iptacopan 200 mg in capsule form, taken twice daily. The study treatment period begins on Day 1, which corresponds to the end of treatment visit from the parent study. Following this, participants attend on-site visits every four months. After the last dose of study treatment, a safety follow-up tele-visit will be conducted seven days later to collect any adverse event information. Throughout the study, researchers will evaluate the number of participants experiencing adverse events and serious adverse events over up to four years. They will also monitor the absence of thrombotic microangiopathy TMA manifestations without anti-C5 antibody treatment, TMA response status, kidney function measured by estimated glomerular filtration rate eGFR, chronic kidney disease stage, dialysis requirement status, and TMA-related adverse events. Participants are expected to comply with regular visits and safety assessments during the study duration.
CONDITIONS
Brief Title
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here